zm-h1505r
Small moleculeexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Feb 29, 2020 (NCT04220801)
Timeline
Indications
Mechanism of action
- Hepatitis B virusINHIBITOR
Hepatitis B virus inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07095855 | Phase 3 | Aug 31, 2025 | Shanghai Zhimeng Biopharma, Inc. |
| NCT05484466 | Phase 2 | Nov 15, 2022 | Jinlin University, Shanghai Zhimeng Biopharma, Inc., Tigermed Consulting Co., Ltd |
| NCT05470829 | Phase 1 | May 27, 2021 | Jinlin University, Shanghai Zhimeng Biopharma, Inc., Yanbian University |
| NCT04220801 | Phase 1 | Feb 29, 2020 | Shanghai Zhimeng Biopharma, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai Zhimeng Biopharma, Inc. | For profit | 4 | 4 | 3 | 2020 |
| Jinlin University | Academic/Hospital | 2 | 0 | 2 | 2021 |
| Tigermed Consulting Co., Ltd | For profit | 1 | 0 | 1 | 2022 |
| Yanbian University | Academic/Hospital | 1 | 0 | 1 | 2021 |
4 organizations
Page 1 / 1